STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?

4:10 AM ETDeveloping

Health Desk

2026-08-27-mortified-mcinnes-takes-responsibility-for-rangers-european-exit — WarpBeat previously cleared still

In the Phase 2 TRANQUILITY study, the drug, pacibekitug, led to sustained decreases in biomarkers of inflammation, according to results presented Saturday at the European Society of Cardiology’s annual meeting in Munich.

Investigators reported a dose-dependent drop in biomarker levels on certain measures, meaning higher doses led to greater reductions, a sign the drug is having an effect.

What's confirmed

What's still developing

In the Phase 2 TRANQUILITY study, the drug, pacibekitug, led to sustained decreases in biomarkers of inflammation, according to results presented Saturday at the European Society of Cardiology’s annual meeting in Munich.
Investigators reported a dose-dependent drop in biomarker levels on certain measures, meaning higher doses led to greater reductions, a sign the drug is having an effect.

Sources

STATlink